Multiparametric MR imaging for detection of clinically significant prostate cancer: A validation cohort study with transperineal template prostate mapping as the reference standard

Radiology

Volumn 268, Issue 3, 2013, Pages 761-769

  Arumainayagam, Nimalan ^a   Ahmed, Hashim U ^a   Moore, Caroline M ^a   Freeman, Alex ^b   Allen, Clare ^b   Sohaib, S Aslam ^c   Kirkham, Alex ^b   Van Der Meulen, Jan ^d   Emberton, Mark ^a,e  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GADOTERATE MEGLUMINE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANALYTICAL PARAMETERS; AREA UNDER THE CURVE; ARTICLE; CANCER DIAGNOSIS; COHORT ANALYSIS; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST ACCURACY STUDY; DIFFUSION WEIGHTED IMAGING; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; STANDARD; TRANSPERINEAL TEMPLATE PROSTATE MAPPING; VALIDATION STUDY;

AGED; COHORT STUDIES; GREAT BRITAIN; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SUBTRACTION TECHNIQUE;

EID: 84883184816     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.13120641     Document Type: Article

References (39)

1. Catto JW, Robinson MC, Albertsen PC, et al. Suitability of PSA-detected localised prostate cancers for focal therapy: experience from the ProtecT study. Br J Cancer 2011;105(7):931-937 .
2. Onik G, Miessau M, Bostwick DG. Threedimensional prostate mapping biopsy has a potentially significant impact on prostate cancer management. J Clin Oncol 2009;27(26): 4321-4326.
3. Djavan B, Ravery V, Zlotta A, et al. Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop? J Urol 2001;166(5): 1679-1683.
4. Lange D, Zappavigna C, Hamidizadeh R, Goldenberg SL, Paterson RF, Chew BH. Bacterial sepsis after prostate biopsy - a new perspective. Urology 2009;74(6): 1200-1205.
5. Ahmed HU, Kirkham A, Arya M, et al. Is it time to consider a role for MRI before prostate biopsy? Nat Rev Clin Oncol 2009;6(4): 197-206.
6. Bossuyt PM, Irwig L, Craig J, Glasziou P. Comparative accuracy: assessing new tests against existing diagnostic pathways. BMJ 2006;332(7549): 1089-1092.
7. Bossuyt PM, Reitsma JB, Bruns DE, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. BMJ 2003;326(7379): 41-44.
8. Dickinson L, Ahmed HU, Allen C, et al. Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. Eur Urol 2011; 59(4): 477-494.
9. Ahmed HU, Emberton M, Kepner G, Kepner J. A biomedical engineering approach to mitigate the errors of prostate biopsy. Nat Rev Urol 2012;9(4): 227-231.
10. Kepner GR, Kepner JV. Transperineal prostate biopsy: analysis of a uniform core sampling pattern that yields data on tumor volume limits in negative biopsies. Theor Biol Med Model 2010;7:23.
11. Ahmed HU, Hu Y, Carter T, et al. Characterizing clinically significant prostate cancer using template prostate mapping biopsy. J Urol 2011;186(2): 458-464.
12. Lord SJ, Staub LP, Bossuyt PM, Irwig LM. Target practice: choosing target conditions for test accuracy studies that are relevant to clinical practice. BMJ 2011;343:d4684.
13. Goto Y, Ohori M, Arakawa A, Kattan MW, Wheeler TM, Scardino PT. Distinguishing clinically important from unimportant prostate cancers before treatment: value of systematic biopsies. J Urol 1996;156(3): 1059-1063.
14. Epstein JI, Pizov G, Walsh PC. Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer 1993; 71(11): 3582-3593.
15. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994; 271(5): 368-374.
16. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005;293(17): 2095-2101.
17. Stamey TA, Freiha FS, McNeal JE, Redwine EA, Whittemore AS, Schmid HP. Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 1993;71(3 Suppl): 933-938.
18. Stark JR, Perner S, Stampfer MJ, et al. Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? J Clin Oncol 2009;27(21): 3459-3464.
19. Kirkham APS, Emberton M, Allen C. How good is MRI at detecting and characterising cancer within the prostate? Eur Urol 2006;50(6):1163-1174; discussion 1175.
20. Kurhanewicz J, Vigneron D, Carroll P, Coakley F. Multiparametric magnetic resonance imaging in prostate cancer: present and future. Curr Opin Urol 2008;18(1): 71-77.
21. Haider MA, van der Kwast TH, Tanguay J, et al. Combined T2-weighted and diffusion- weighted MRI for localization of prostate cancer. AJR Am J Roentgenol 2007;189(2): 323-328.
22. Kozlowski P, Chang SD, Jones EC, Berean KW, Chen H, Goldenberg SL. Combined diffusion- weighted and dynamic contrast-enhanced MRI for prostate cancer diagnosis - correlation with biopsy and histopathology. J Magn Reson Imaging 2006;24(1): 108-113.
23. Villers A, Puech P, Mouton D, Leroy X, Ballereau C, Lemaitre L. Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings. J Urol 2006;176(6 Pt 1): 2432-2437.
24. Delongchamps NB, Rouanne M, Flam T, et al. Multiparametric magnetic resonance imaging for the detection and localization of prostate cancer: combination of T2-weighted, dynamic contrast-enhanced and diffusion- weighted imaging. BJU Int 2011;107(9): 1411-1418 .
25. Mulherin SA, Miller WC. Spectrum bias or spectrum effect? Subgroup variation in diagnostic test evaluation. Ann Intern Med 2002; 137(7): 598-602.
26. Esserman L, Shieh Y, Thompson I. Rethinking screening for breast cancer and prostate cancer. JAMA 2009;302(15): 1685-1692.
27. Ahmed HU. The index lesion and the origin of prostate cancer. N Engl J Med 2009;361(17): 1704-1706.
28. Wolters T, Roobol MJ, van Leeuwen PJ, et al. A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial. J Urol 2011;185(1): 121-125.
29. Taira AV, Merrick GS, Galbreath RW, et al. Performance of transperineal templateguided mapping biopsy in detecting prostate cancer in the initial and repeat biopsy setting. Prostate Cancer Prostatic Dis 2010; 13(1): 71-77.
30. Barzell WE, Melamed MR. Appropriate patient selection in the focal treatment of prostate cancer: the role of transperineal 3-dimensional pathologic mapping of the prostate - a 4-year experience. Urology 2007;70(6 Suppl): 27-35.
31. Barqawi AB, Rove KO, Gholizadeh S, O'Donnell CI, Koul H, Crawford ED. The role of 3-dimensional mapping biopsy in decision making for treatment of apparent early stage prostate cancer. J Urol 2011;186(1): 80-85.
32. Crawford ED, Wilson SS, Torkko KC, et al. Clinical staging of prostate cancer: a computer-simulated study of transperineal prostate biopsy. BJU Int 2005;96(7): 999-1004.
33. Sciarra A, Barentsz J, Bjartell A, et al. Advances in magnetic resonance imaging: how they are changing the management of prostate cancer. Eur Urol 2011;59(6): 962-977.
34. Hoeks CM, Barentsz JO, Hambrock T, et al. Prostate cancer: multiparametric MR imaging for detection, localization, and staging. Radiology 2011;261(1): 46-66.
35. Bonekamp D, Jacobs MA, El-Khouli R, Stoianovici D, Macura KJ. Advancements in MR imaging of the prostate: from diagnosis to interventions. RadioGraphics 2011;31(3): 677-703.
36. Pinto F, Totaro A, Calarco A, et al. Imaging in prostate cancer diagnosis: present role and future perspectives. Urol Int 2011; 86(4): 373-382.
37. Cornud F, Delongchamps NB, Mozer P, et al. Value of multiparametric MRI in the work-up of prostate cancer. Curr Urol Rep 2012;13(1): 82-92.
38. Ahmed HU, Freeman A, Kirkham A, et al. Focal therapy for localized prostate cancer: a phase I/II trial. J Urol 2011;185(4): 1246-1254.
39. Ahmed HU, Pendse D, Illing R, Allen C, van der Meulen JH, Emberton M. Will focal therapy become a standard of care for men with localized prostate cancer? Nat Clin Pract Oncol 2007;4(11): 632-642.